Home > PJ (current issue) > Pharmaceutical Care Awards

PJ Online homeThe Pharmaceutical Journal
Vol 279 No 7459 p10
7 July 2007

This article
Reprint   Photocopy

PDF 140K, Acrobat Reader

Pharmaceutical Care Awards 2006

Improving the care of anorexia-cachexia patients

Improving the experience of the anorexia-cachexia syndrome for patients with cancer

Pharmaceutical Care Awards

The Pharmaceutical Care Awards 2006 were presented at a celebratory dinner on 29 June 2007 at Apothecaries’ Hall, London. The dinner followed a conference at the Royal Pharmaceutical Society’s headquarters, where the finalists presented their projects to an audience of invited guests. The awards, organised by The Pharmaceutical Journal, are sponsored by GlaxoSmithKline and the Company Chemists’ Association


County Durham and Darlington NHS Foundation Trust

Inga Andrew, Macmillan senior clinical pharmacist

Colette Hawkins, consultant in palliative medicine

Kerry Waterfield, staff grade in palliative medicine

Graeme Kirkpatrick, deputy chief pharmacist and Keith Holden, principal clinical pharmacist

City Hospitals Sunderland NHS Foundation Trust

Stephen Williams, Macmillan development manager

Tony Hildreth, trust medical statistician and deputy head of research

Cyril Chantler and Inga Andrew

Sir Cyril Chantler with Inga Andrew

Standardising methods which any health care professional can use to improve the care of cancer patients with anorexia-cachexia syndrome (ACS) was the subject of a winning project from County Durham and Darlington NHS Foundation Trust, run by a Macmillan senior cancer pharmacist.

A baseline review at the hospital found that staff who came into contact with cancer patients had variable understanding of ACS and that there was a lack of useful tools about how to manage the syndrome.

An audit was undertaken of 23 patients suffering from the syndrome, using the Patient Generated Subjective Global Assessment tool (recording eating habits, symptoms, activity-related problems etc). A diet history, drug history and a medicines use review were also carried out.

A total of 147 symptoms were reported (77 of which did not appear to have been managed by pharmacological means and were active problems for the patients) and a management plan was established.

This included 80 recommended medication changes, non-pharmacological advice (on topics such as oral hygiene) and referrals to a dietitian. Prescribing guidelines and shared care agreements were written for several of the medicines.

Presenting the project, Inga Andrew explained that these were simple strategies that any health care professional could use, and the team wanted to standardise them. This led to the development of a resource pack to help with the systematic assessment and management of common problems experienced by ACS patients. The pack includes an abridged version of the patient assessment tool, simple dietetic and physiotherapy management pathways, a symptom management tool and leaflets for patients and carers.

The Durham Macmillan cachexia pack is currently being piloted locally and is expected to be launched nationally at the end of the year.

Previously, a large number of patients with ACS will have had their symptoms unrecognised or unmanaged. This study is ongoing but the researchers’ impression is that there has been an improvement in the symptoms and well-being of patients.

Back to Top


©The Pharmaceutical Journal